Blueprint Medicines shares are trading higher after Wells Fargo upgraded the stock from Equal-Weight to Overweight.
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo has upgraded Blueprint Medicines' stock from Equal-Weight to Overweight, leading to a rise in the company's shares.
July 31, 2023 | 2:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Blueprint Medicines' stock has been upgraded by Wells Fargo, which has resulted in a rise in the company's share price.
The upgrade from Wells Fargo is a positive signal for investors, indicating a bullish outlook for Blueprint Medicines. This has led to increased buying pressure, resulting in a rise in the company's share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100